Clinical pharmacokinetics of the irinotecan metabolite 4- piperidinopiperidine and its possible clinical importance

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 1, 2000, Pages 9-14

  Dodds, Helen M ^c   Clarke, Stephen J ^c   Findlay, Michael ^a   Bishop, James F ^c   Robert, Jacques ^b   Rivory, Laurent P ^c  

^a WELLINGTON HOSPITAL   (New Zealand)

^b INSTITUT BERGONIÉ   (France)

^c NONE

Author keywords

4PP; CPT 11; High performance liquid chromatography; Tandem mass spectrometry; Turboionspray

Indexed keywords

4 PIPERIDINOPIPERIDINE; DRUG METABOLITE; IRINOTECAN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG RESEARCH; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

EID: 0002757795     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00006750     Document Type: Article

References (13)

1. rd HA, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14: 1128
2. 2. Rivory LP, Robert J (1995) Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives. Pharmacol Ther 68: 269
3. 3. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, Nagai E (1994) Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumour agent, by carboxylesterase. Biol Pharm Bull 17: 662
4. 4. Rivory LP, Bowles MR, Robert J, Pond SM (1996) Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52: 1103
5. 5. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumour effect of CPT-11. Cancer Res 51: 4187
6. 6. O'Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M (1999) Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 5: 181
7. 7. Onishi Y, Oguro M, Kizaki H (1997) A lymphoma cell line resistant of 4-piperidinopiperidine was less sensitive to CPT-11. Cancer Chemother Pharmacol 39: 473
8. 8. Krouwer JS, Rabinowitz R (1984) How to improve estimates of imprecision. Clin Chem 30: 290
9. 9. Rivory LP, Robert J (1995) Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 36: 176
10. 10. Rivory LP, Robert J (1994) Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J Chromatogr B Biomed Sci Appl 661: 133
11. 11. Rivory LP, Haaz M-C, Canal P, Lokiec F, Armand J-P, Robert J (1997) Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 3: 1261
12. 12. Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Herait P, Armand JP, Bugat R, Clavel M, Marty ME (1995) Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 6: 141
13. 13. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain M (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). J Clin Invest 101: 847